SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, …
Author: Business Wire
Global Optometry/Eye Exam Equipment Market by Type, End User – Forecast to 2022 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Optometry/Eye Exam Equipment Market by Type, End User – Global Forecast to 2022” report has been added to ResearchAndMarkets.com’s offering. “The eye exam equipment market is projected to grow at a CAGR of 6.0% between 201…
The Global Ophthalmic Surgical Instruments Market is Estimated to Reach USD 11.18 Billion by 2022 from USD 8.36 Billion in 2017, at a CAGR of 6.0% – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmic Surgical Instruments Market – Global Forecast to 2022” report has been added to ResearchAndMarkets.com’s offering. The global ophthalmic surgical instruments market is expected to reach USD 11.18 billion by 2022…
Top Student Inventors Awarded Lemelson-MIT Student Prize
CAMBRIDGE, Mass.–(BUSINESS WIRE)–#InvenTeams–Following a nationwide search for the most inventive college students, the Lemelson-MIT Program today announced the winners of the 2018 Lemelson-MIT Student Prize. The Program awarded a total of $80,000 i…
Hemovent Starts GLP in vivo Trial for Long-Term Use of Its Next-Gen ExtraCorporeal Membrane Oxygenation (ECMO) System
AACHEN, Germany–(BUSINESS WIRE)–Hemovent GmbH announced today that it has commenced a GLP in vivo study for the long-term (7 days) use of its novel and portable artificial lung technology platform, designed for a wide range of indications from ExtraC…
Avedro Names James Schuermann Chief Business Officer
WALTHAM, Mass.–(BUSINESS WIRE)–#crosslinking–Avedro, Inc., an ophthalmic pharmaceutical and medical device company and the world leader in corneal remodeling, today announced that James F. Schuermann has joined the company as Chief Business Officer (CBO). Mr. Schuermann will lead the global government affairs, health economics and reimbursement, communications, sales, field service, marketing and business development functions and will report to Avedro’s Chief Executive Officer, Reza Zadno. “Jim joins us a
Swiss Advanced Visionが白内障向けにリアルタイムのオートフォーカス機能を搭載した能動眼内レンズ構想を発表
スイス・ヌーシャテル–(BUSINESS WIRE)–（ビジネスワイヤ）– Swiss Advanced Vision（SAV-IOL）は、世界の眼内レンズ（IOL）市場を根底から変革することになるR-TASCプロジェクトの発足について発表しました。 白内障は世界の失明症例のうち51%の原因となっており、失明者は約3500万人に上ります。世界市場が拡大している眼内レンズは2017年の推計35億米ドルから2022年までに45億6000万米ドルに達すると見込まれており、年平均成長率（CAGR）は5.4%となります。この市場成長を促進しているのが、人口高齢化、世界における眼疾患および糖尿病の増加、白内障による失明を管理・治療するための政府イニシアチブです。 ただ、市場規模の大きさにもかかわらず、眼内レンズには目立った革新成果が生まれてきませんでした。SAV-IOLは眼内レンズに取り組むためのまったく新しい手法を開発しています。R-TASC（Real-Time Autofocus Servo Control、リアルタイム・オートフォーカス・サーボ・コントロール）は、リアルタイムのオート
Swiss Advanced Vision上市用於白內障手術的即時自動對焦主動式人工水晶體概念
瑞士紐沙提勒–(BUSINESS WIRE)–(美國商業資訊) — Swiss Advanced Vision (SAV-IOL)宣布啟動R-TASC計畫，以此攪局全球人工晶體(IOL)市場。 全球失明者中有51%（約3500萬人）為白內障所致。IOL是成長中的全球性市場，預計市場規模將從2017年的35億美元增至2022年的45.6億美元，年複合成長率達5.4%。驅動該市場成長的是人口高齡化、全球眼疾和糖尿病發病率的攀升，以及政府在控制和治療白內障所致失明方面的措施。 然而，儘管有此市場規模，IOL領域值得關注的創新卻寥寥無幾。SAV-IOL正在針對IOL制定一種全新的方法。R-TASC（Real-Time Autofocus Servo Control，即時自動對焦伺服控制）是一種即時自動對焦和無線互聯的主動式水晶體。現有的所有水晶體均為定焦，視光學效果會有所犧牲，例如配光曲線、解析度和視覺干擾。這是其靜態設計的固有弊病，無法克服白內障手術後的（視力）調節功能失調問題。 R-TASC旨在徹底恢復眼精水晶體正常情況下所提供的調節功能。R-TASC水晶體採用一個能量擷取系統，能
Swiss Advanced Vision上市用于白内障手术的实时自动对焦主动式人工晶体概念
瑞士纳沙泰尔–(BUSINESS WIRE)–(美国商业资讯) — Swiss Advanced Vision (SAV-IOL)宣布启动R-TASC项目，以此搅局全球人工晶体(IOL)市场。 全球失明者中有51%（约3500万人）为白内障所致。IOL是增长中的全球性市场，预计市场规模将从2017年的35亿美元增至2022年的45.6亿美元，复合年均增长率达5.4%。驱动该市场增长的是人口老龄化、全球眼疾和糖尿病发病率的攀升，以及政府在控制和治疗白内障所致失明方面的举措。 然而，尽管有此市场规模，IOL领域值得关注的创新却寥寥无几。SAV-IOL正在针对IOL制定一种全新的方法。R-TASC（Real-Time Autofocus Servo Control，实时自动对焦伺服控制）是一种实时自动对焦和无线互联的主动式晶状体。现有的所有晶状体均为定焦，视光学效果会有所牺牲，例如配光曲线、分辨率和视觉干扰。这是其静态设计的固有弊病，无法克服白内障手术后的（视力）调节功能失调问题。 R-TASC旨在彻底恢复眼晶状体正常情况下所提供的调节功能。R-TASC晶状体基于一个能量捕捉系统，能
Swiss Advanced Vision presenta el concepto de lente intraocular activa con enfoque automático en tiempo real para la cirugía de cataratas
NEUCHATEL, Suiza–(BUSINESS WIRE)–Swiss Advanced Vision (SAV-IOL) ha anunciado el lanzamiento del Proyecto R-TASC, destinado a transformar el mercado global de las lentes intraoculares (LIO). Las cataratas son responsables del 51 % de los casos de ceguera del mundo, lo que representa unos 35 millones de personas. El mercado global de las LIO está en pleno crecimiento, está previsto que alcance los 4560 millones de dólares en 2022, desde los aproximadamente 3500 millones de dólares en 2017, a u
Swiss Advanced Vision lança conceito de lente intraocular com autofoco em tempo real para cirurgia de catarata
NEUCHATEL, Suíça–(BUSINESS WIRE)–Swiss Advanced Vision (SAV-IOL) anunciou o lançamento do Projeto R-TASC, criado para revolucionar o mercado global de lentes intraoculares (LIO). A catarata é responsável por 51% dos casos de cegueira no mundo, o que representa cerca de 35 milhões de pessoas. As LIOS, que constituem um mercado global crescente, alcançaram 4,56 bilhões de dólares em 2022, com um crescimento anual de 5,4% em relação aos 3,50 bilhões de dólares de 2017. O que impulsiona o crescim
Riassunto: Swiss Advanced Vision lancia un concetto di lente intraoculare attiva autofocalizzante in tempo reale per intervento di cataratta
NEUCHATEL, Svizzera–(BUSINESS WIRE)–Swiss Advanced Vision (SAV-IOL) ha annunciato il lancio di Project R-TASC, che rivoluzionerà il mercato globale delle lenti intraoculari (IOL). La cataratta è responsabile del 51% dei casi di cecità nel mondo, ovvero circa 35 milioni di persone. Quello delle IOL è un mercato globale in aumento, che si prevede raggiungerà volumi di 4,56 miliardi di dollari USA entro il 2022 da uno stimato 3,50 miliardi nel 2017, ad un tasso di crescita annuale composto (CAGR
Samenvatting: Swiss Advanced Vision lanceert actief intraoculair lensconcept met real-time autofocus voor staaroperaties
NEUCHATEL, Switzerland–(BUSINESS WIRE)–Swiss Advanced Vision (SAV-IOL) heeft de lancering van Project R-TASC aankondigd, ingesteld om de global intraocular lens (IOL) markt te verstoren. Staar is wereldwijd gezien verantwoordelijk voor 51% van de bli…
Swiss Advanced Vision lance le concept de lentille intraoculaire active avec mise au point automatique en temps réel pour la chirurgie de la cataracte
NEUCHÂTEL, Suisse–(BUSINESS WIRE)–Swiss Advanced Vision (SAV-IOL) a annoncé le lancement du projet R-TASC, destiné à bouleverser le marché mondial de la lentille intraoculaire (LIO). Les cataractes sont responsables de 51 % des cas de cécité dans le monde, représentant environ 35 millions de personnes. Avec un marché mondial en pleine croissance, les LIO devraient atteindre 4,56 milliards USD d’ici 2022 contre une valeur estimée de 3,50 milliards en 2017, soit un taux de croissance annuel cum
Swiss Advanced Vision präsentiert aktives Intraokularlinsenkonzept mit Real-Time Autofokus für die Kataraktchirurgie
NEUCHATEL, Schweiz–(BUSINESS WIRE)–Swiss Advanced Vision (SAV-IOL) meldete den Start von Project R-TASC, das den weltweiten Markt für Intraokularlinsen (IOL) in Bewegung bringen wird. Katarakte sind für 51% der weltweiten Erblindungen ursächlich, was etwa 35 Millionen Menschen entspricht. Als weltweit wachsender Markt wird der IOL-Markt von geschätzten 3,50 Milliarden. USD im Jahr 2017 bis 2022 voraussichtlich ein Volumen von 4,56 Milliarden. USD erreichen, bei einer CAGR von 5,4 %. Treiber d
Swiss Advanced Vision Launches Active Intraocular Lens Concept with Real-Time Autofocus for Cataract Surgery
NEUCHATEL, Switzerland–(BUSINESS WIRE)–Swiss Advanced Vision is developing an active intraocular lens, set to disrupt the global IOL market and transform patients vision without compromise.
Second Sight Announces Dr. Robert Greenberg’s Resignation from Board of Directors and as an Officer of the Company
LOS ANGELES–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today announced that Dr. Robert Greenberg, MD, PhD has resigned from the Company’s Board of Directors and the Company, effective April 3, 2018. Dr. Robert Greenberg has served on the Board of Directors since May 2003, as Chief E
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals grants an inducement award in connection with the appointment of Eric Trachtenberg as General Counsel and Corporate Secretary.
Data from BioTime’s OpRegen® Program to Be Presented at the Fifth Annual Retinal Cell and Gene Therapy Innovation Summit
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that data from the ongoing OpRegen® trial will be presented at the upcoming Fifth Annual Retinal Cell and Gene Therapy Innovation Summit. The presentation will take place on April 27th, 2018 from 8:15am – 8:30am local time, in Honolulu, Hawaii. The OpRegen® data will be presented by one of our principal investigators, Dr. Eyal Banin, Hada
Kala Pharmaceuticals to Present at the 2018 American Society of Cataract and Refractive Surgery Annual Meeting (ASCRS) and at the Ophthalmology Innovation Summit at ASCRS
WALTHAM, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals announces that it will be presenting at OIS@ASCRS and data from trials conducted with INVELTYS™ will be presented at ASCRS.